ESPERION THERAPEUTICS INC NE - NOTE 4.000%11/1 Institutional Ownership

CUSIP: 29664WAB1

13F Institutional Holders and Ownership History from Q4 2021 to Q4 2025

Type / Class
Debt / NOTE 4.000%11/1
All holders as of 31 Dec 2025
Q4 2025
Total 13F principal
$0
Total reported market value
$0
Principal change
-$28,696,440
Market value change
-$40,994,280
Number of holders
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 29664WAB1?
CUSIP 29664WAB1 identifies 29664WAB1 - ESPERION THERAPEUTICS INC NE - NOTE 4.000%11/1 in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

As of 31 Dec 2025, 0 institutional investors reported holding $0 in principal (par value) of ESPERION THERAPEUTICS INC NE - NOTE 4.000%11/1.

Institutional Holders of ESPERION THERAPEUTICS INC NE - NOTE 4.000%11/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2025 Q4 $0 $0 -$40,994,280 0
2025 Q3 $28,696,440 $40,994,280 +$186,254 99.8% 9
2025 Q2 $21,445,940 $40,691,968 +$258,902 98.57% 11
2025 Q1 $17,805,940 $37,176,006 +$4,762,266 98.3% 9
2024 Q4 $33,246,000 $32,179,247 -$171,476,277 96.97% 6
2024 Q3 $206,228,879 $255,900,035 -$4,680,942 94.87% 16
2024 Q2 $152,469,254 $187,829,878 +$194,776 92.31% 18
2024 Q1 $168,363,404 $171,853,927 -$14,901,542,141 83.01% 17
2023 Q4 $210,454,000 $122,864,861 +$10,846,961 58.34% 18
2023 Q3 $192,120,851 $110,572,628 -$4,399,266 52.0% 17
2023 Q2 $198,299,351 $109,095,639 -$6,106,943 49.71% 18
2023 Q1 $236,594,851 $103,500,121 -$397,411 40.06% 20
2022 Q4 $235,496,164 $132,860,346 +$4,389,560 54.96% 20
2022 Q3 $214,894,764 $128,456,175 -$42,773 55.78% 19
2022 Q2 $214,994,764 $125,766,000 +$772,275 54.43% 19
2022 Q1 $212,146,264 $118,647,578 +$5,205,374 51.57% 20
2021 Q4 $199,553,764 $115,520,638 +$115,520,638 52.75% 17